ClinicalTrials.gg
CompletedNCT02336230Updated Mar 17, 2022Results posted

A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)

A Phase 3 interventional study of remestemcel-L in Grade B aGVHD, Grade C aGVHD and Grade D aGVHD, sponsored by Mesoblast, Inc.. Completed at 20 sites in United States. Open to participants aged 2 Months to 17 Years. Per ClinicalTrials.gov, last updated 2022-03-17.

Sponsored by Mesoblast, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
2 Months to 17 Years
Sex
All
01

Study summary

The study plans to treat at least 60 pediatric participants, male and female, between the ages of 2 months and 17 years inclusive with aGVHD following allogeneic hematopoietic stem cell transplant (HSCT) that has failed to respond to treatment with systemic corticosteroid therapy. Participants may have Grades C and D aGVHD involving the skin, liver and/or gastrointestinal (GI) tract or Grade B aGVHD involving the liver and/or GI tract, with or without concomitant skin disease.

Read the detailed description

Remestemcel-L will be evaluated in pediatric participants with aGVHD following allogeneic HSCT that has failed to respond to treatment with systemic corticosteroid therapy.

02

Conditions studied

  • Grade B aGVHD
  • Grade C aGVHD
  • Grade D aGVHD

Keywords

  • GVHD
03

In context

Lead sponsor

Mesoblast, Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 4 (25%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is diagnosed with Grade B-D acute requiring systemic therapy. The participant may have Grade C or D aGVHD involving the skin, liver, and/or GI tract or may have Grade B aGVHD involving the liver and/or GI tract, with or without concomitant skin disease. Acute GVHD is defined as the presence of skin rash and/or persistent nausea, vomiting, and/or diarrhea and/or cholestasis presenting in a context in which aGVHD is likely to occur and where other etiologies such as drug rash, enteric infection, or hepatotoxic syndromes are unlikely or have been ruled out.
  2. Participant has failed to respond to steroid treatment, with failure to respond defined as any Grade B-D [International Bone Marrow Transplant Registry (IBMTR) grading] aGVHD that shows progression within 3 days, or no improvement within 7 days of consecutive treatment with 2 mg/kg/day methylprednisolone or equivalent.
  3. Participant must be able to be treated with remestemcel-L within 4 days of signing of .
  4. Participants who have had persistent GI GVHD manifested by diarrhea with stool volume \< 500 mL/kg/day (for participants >50 kg) or \<30 mL/kg/day (for participants ≤50 kg). See GVHD Organ Severity Criteria (Table 2) for values in mL/m\^2. In the absence of nausea or vomiting, participants could have been considered to have Grade B GVHD if:

    1. other causes of diarrhea had been ruled out (eg, Clostridium difficile, adenovirus or cytomegalovirus [CMV] infection, or oral magnesium administration), and if
    2. the low stool volume reflected the effects of fasting, narcotics, or antidiarrheal medications.
  5. Participant must have adequate renal function as defined by a calculated of >30 mL/min per 1.73 m\^2. For participants 1 to 18 years of age, creatinine clearance is calculated using the Bedside Schwartz equation:

    (GFR, in mL/min per 1.73 m\^2) = (0.413 * height [cm])/serum creatinine (mg/dL)

    For participants younger than 1 year of age, renal function is determined using the Schwartz equation adjusted for this age group:

    Creatinine clearance (mL/min per 1.73 m\^2= (height [cm] x 0.45)/ (serum creatinine [mg/dL]).

  6. Participant has a minimum /Lansky Performance Level of at least 30 at the time of study entry.
  7. Participant (or legal representative where appropriate) must be capable of providing written informed consent.
  8. Female participants of (≥10 years of age) are required to use a medically accepted method of and to agree to continue use of this method for the duration of the study and for the follow-up time period. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
  9. Male participants with partners of childbearing potential must agree to use adequate contraception (barrier method or abstinence) during the study, including the follow-up time period.
  10. The participant must be willing and able to comply with study requirements, remain at the clinic, and return to the clinic for the follow-up evaluation during the study period, as specified in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participant has Grade B aGvHD with skin-only involvement.
  2. Participant has received any therapy to treat aGVHD prior to screening.
  3. Participant has received systemic agents other than and prophylactic agents for primary treatment of aGVHD.
  4. Participant shows evidence of diffuse alveolar hemorrhage or other active pulmonary disease, which is likely to require more than 2L of oxygen via face mask, or an estimated fractional inspired oxygen concentration (FiO2) of 28% via other delivery methods in order to sustain an O2 saturation of 92%.
  5. Participant has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the participant including but not limited to uncontrolled infection, heart failure, or pulmonary hypertension.
  6. Participant has received any stem cell agents (other than hematopoietic graft) during study participation or within 30 days prior to study entry. Previous use of irradiated granulocytes within 30 days is permitted.
  7. Participant has received an transplant for a solid tumor disease.
  8. Participant has had prior treatment with mesenchymal stem cells (MSCs), including remestemcel-L.
  9. Participant shows evidence of severe (required treatment) hepatic veno-occlusive disease (VOD) or sinusoidal obstruction at screening.
  10. Participant had positive laboratory test results indicating infection with the (HIV) at any time and/or active or C virus infection within 3 months prior to screening.
  11. Participant shows evidence of encephalopathy, as defined by a change in mental status since the onset of aGVHD.
  12. Participant is a female who is pregnant, lactating, or is planning a pregnancy during study participation, or in the follow-up period.
  13. Participant currently being treated for a solid tumor .
  14. Participant has participated in any interventional clinical trial for an aGVHD therapeutic agent. However, in exceptional cases, experimental agents may have been administered to enrolled participants at the Investigator's discretion.
  15. Participant has participated or is currently participating in any autologous and allogeneic stem cell or gene therapy study for the treatment of aGVHD. Participants participating in investigative protocols aimed at modification of the transplant graft (such as T-cell depletion) or aimed at modification of the conditioning regimen are allowed in the study.
  16. Participant has a known to dimethyl sulfoxide (DMSO) or to murine, porcine, or bovine proteins.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Remestemcel-L 2×10^6 MSCs/kg

    Participants were treated with intravenous (IV) remestemcel-L at a dose of 2×10\^6 mesenchymal stromal cells (MSCs)/kilogram (kg) actual body weight at Screening, twice per week, for each of 4 consecutive weeks (initial therapy) given at least 3 days apart and no more than 5 days apart for any infusion. Eligible participants received an additional once per week infusion, for each of 4 consecutive weeks (continued therapy) of remestemcel-L and twice per week infusions, for each of 4 consecutive weeks (aGVHD flare therapy) of remestemcel-L at the same initial therapy dose of 2×10\^6 MSCs/kg actual body weight at Screening.

    Drug: remestemcel-L

Interventions

  • Participants were treated with IV remestemcel-L at a dose of 2 x 10\^6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions were administered at least 3 days apart and no more than 5 days apart for any infusion.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy

    ORR was defined as the percentage of participants who had achieved overall response. Overall response was defined as complete response (CR) plus partial response (PR) as per aGVHD response criteria. CR was defined as resolution of aGVHD in all involved organs. PR was defined as organ improvement of at least 1 stage without worsening of any other organ.

    Time frame: Day 28

Secondary outcomes

  1. Overall Survival (OS) Rate at Day 100 Post Initiation of Therapy

    Overall survival rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy.

    Time frame: Day 100

  2. OS Rate at Day 100 Post Initiation of Therapy, Stratified by Responder Status at Day 28

    Overall survival rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy.

    Time frame: Day 100

  3. OS Rate at Day 100 Post Initiation of Therapy, Stratified by Baseline aGVHD Grade

    OS rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy. Maximum severity of acute GVHD was assessed by using International Bone Marrow Transplant Registry (IBMTR) index. The severity index was defined as: Grade A (skin Stage 1: extent of rash \<25%); Grade B (skin Stage 2: extent of rash 25 to 50% or liver Stage 1 to 2: total bilirubin 34 to 102 micromoles per liter \[mcmol/L\] or intestinal tract Stage 1 to 2: volume of diarrhea 550 to 1500 milliliters per day \[mL/day\]); Grade C (skin Stage 3: extent of rash \> 50% or liver Stage 3: total bilirubin 103 to 255 mcmol/L or intestinal tract Stage 3: volume of diarrhea \>1500 mL/day); Grade D (skin Stage 4: extent of rash bullae or liver Stage 4: total bilirubin \>255 or intestinal tract Stage 4: volume of diarrhea severe pain and ileus).

    Time frame: Day 100

  4. OS Rate at Day 100 Post Initiation of Therapy, Stratified by Organ Involvement

    OS rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy. The data was summarized for organ involvement: skin only, lower GI only, and multi-organ.

    Time frame: Day 100

  5. OR Rate at Day 56 and 100 Post Initiation of Therapy

    OR rate was defined as the percentage of participants who had achieved overall response. Overall response was defined as CR plus PR as per aGVHD response criteria. CR was defined as resolution of aGVHD in all involved organs. PR was defined as organ improvement of at least 1 stage without worsening of any other organ.

    Time frame: Day 56 and Day 100

07

Results

Posted Mar 17, 2022

Participant flow

Participant flow — Overall Study
MilestoneRemestemcel-L 2×10^6 MSCs/kg
Started55
Full analysis set (fas)55
Safety analysis population54
Completed42
Not completed13
Withdrew: Adverse event1
Withdrew: Withdrawal of consent1
Withdrew: Death9
Withdrew: Dose not received due to shipping delay1
Withdrew: Discontinuation of msc infusion1

Outcome measures

PrimaryOverall Response Rate (ORR) at Day 28 Post Initiation of Therapy

ORR was defined as the percentage of participants who had achieved overall response. Overall response was defined as complete response (CR) plus partial response (PR) as per aGVHD response criteria. CR was defined as resolution of aGVHD in all involved organs. PR was defined as organ improvement of at least 1 stage without worsening of any other organ.

Time frame:
Day 28
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy
percentage of participantsRemestemcel-L 2×10^6 MSCs/kg
Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy69.1
Statistical analysis
  • Remestemcel-L 2×10^6 MSCs/kg · Binomial Distribution · p = 0.0003 (P-value was calculated from the binomial distribution under the assumption of a 0.45 success rate for the null hypothesis.)
SecondaryOverall Survival (OS) Rate at Day 100 Post Initiation of Therapy

Overall survival rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy.

Time frame:
Day 100
Reported as:
Number · percentage of participants
Overall Survival (OS) Rate at Day 100 Post Initiation of Therapy
percentage of participantsRemestemcel-L 2×10^6 MSCs/kg
Overall Survival (OS) Rate at Day 100 Post Initiation of Therapy74.5
SecondaryOS Rate at Day 100 Post Initiation of Therapy, Stratified by Responder Status at Day 28

Overall survival rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy.

Time frame:
Day 100
Reported as:
Number · percentage of participants
OS Rate at Day 100 Post Initiation of Therapy, Stratified by Responder Status at Day 28
percentage of participantsRemestemcel-L 2×10^6 MSCs/kg
Responders86.8
Non- Responders47.1
Statistical analysis
  • Remestemcel-L 2×10^6 MSCs/kg · CHM test · p = 0.0032 (P-value was from a Cochran-Mantel-Haenszel (CMH) test stratified by baseline aGVHD grade.)
SecondaryOS Rate at Day 100 Post Initiation of Therapy, Stratified by Baseline aGVHD Grade

OS rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy. Maximum severity of acute GVHD was assessed by using International Bone Marrow Transplant Registry (IBMTR) index. The severity index was defined as: Grade A (skin Stage 1: extent of rash \<25%); Grade B (skin Stage 2: extent of rash 25 to 50% or liver Stage 1 to 2: total bilirubin 34 to 102 micromoles per liter \[mcmol/L\] or intestinal tract Stage 1 to 2: volume of diarrhea 550 to 1500 milliliters per day \[mL/day\]); Grade C (skin Stage 3: extent of rash \> 50% or liver Stage 3: total bilirubin 103 to 255 mcmol/L or intestinal tract Stage 3: volume of diarrhea \>1500 mL/day); Grade D (skin Stage 4: extent of rash bullae or liver Stage 4: total bilirubin \>255 or intestinal tract Stage 4: volume of diarrhea severe pain and ileus).

Time frame:
Day 100
Reported as:
Number · percentage of participants
OS Rate at Day 100 Post Initiation of Therapy, Stratified by Baseline aGVHD Grade
percentage of participantsRemestemcel-L 2×10^6 MSCs/kg
Grade B50.0 (11.81 to 88.19)
Grade C82.6 (61.22 to 95.05)
Grade D73.1 (52.21 to 88.43)
SecondaryOS Rate at Day 100 Post Initiation of Therapy, Stratified by Organ Involvement

OS rate was defined as percentage of participants who survived. OS was defined as the time to death from the start of drug therapy. The data was summarized for organ involvement: skin only, lower GI only, and multi-organ.

Time frame:
Day 100
Reported as:
Number · percentage of participants
OS Rate at Day 100 Post Initiation of Therapy, Stratified by Organ Involvement
percentage of participantsRemestemcel-L 2×10^6 MSCs/kg
Skin Only78.6
Lower GI Only76.2
Multi-organ (Any Combination)70.0
SecondaryOR Rate at Day 56 and 100 Post Initiation of Therapy

OR rate was defined as the percentage of participants who had achieved overall response. Overall response was defined as CR plus PR as per aGVHD response criteria. CR was defined as resolution of aGVHD in all involved organs. PR was defined as organ improvement of at least 1 stage without worsening of any other organ.

Time frame:
Day 56 and Day 100
Reported as:
Number · percentage of participants
OR Rate at Day 56 and 100 Post Initiation of Therapy
percentage of participantsRemestemcel-L 2×10^6 MSCs/kg
Day 5658.2
Day 10069.1

Adverse events

Collected over From Baseline through 100 days of follow up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Remestemcel-L 2×10^6 MSCs/kg13/55 (23.6%)35/54 (64.8%)52/54 (96.3%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventRemestemcel-L 2×10^6 MSCs/kg
PyrexiaGeneral disorders5/54
Multiple organ dysfunction syndromeGeneral disorders5/54
Respiratory failureRespiratory, thoracic and mediastinal disorders5/54
Pneumatosis intestinalisGastrointestinal disorders4/54
Acute graft versus host diseaseImmune system disorders3/54
Staphylococcal infectionInfections and infestations3/54
Haemolytic uraemic syndromeBlood and lymphatic system disorders2/54
Graft versus host disease in skinImmune system disorders2/54
BK virus infectionInfections and infestations2/54
Escherichia urinary tract infectionInfections and infestations2/54
Most frequent other events
Showing 10 of 66
Most frequent other events
EventRemestemcel-L 2×10^6 MSCs/kg
PyrexiaGeneral disorders13/54
Abdominal painGastrointestinal disorders10/54
Adenovirus infectionInfections and infestations10/54
HypertensionVascular disorders10/54
VomitingGastrointestinal disorders9/54
ArthralgiaMusculoskeletal and connective tissue disorders8/54
HypotensionVascular disorders8/54
Oedema peripheralGeneral disorders7/54
Epstein-Barr viraemiaInfections and infestations7/54
HyperglycaemiaMetabolism and nutrition disorders7/54

Baseline characteristics

Full analysis set (FAS) included all participants who provided informed consent, were screened, and were found eligible to enter the study.

Age, Continuous
Age, Continuous(years)Remestemcel-L 2×10^6 MSCs/kg
Mean7.3 ± 5.45
Sex: Female, Male
Sex: Female, Male(Participants)Remestemcel-L 2×10^6 MSCs/kg
Female20
Male35
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Remestemcel-L 2×10^6 MSCs/kg
Hispanic or Latino18
Not Hispanic or Latino36
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Remestemcel-L 2×10^6 MSCs/kg
American Indian or Alaska Native3
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American8
White31
More than one race10
Unknown or Not Reported0
08

Study locations

20 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • University of California at San Francisco
    San Francisco, California 94143, United States
  • Children's Hospital Colorado Center for Cancer/Blood Disorders
    Aurora, Colorado 80045, United States
  • Alfred I. DuPont Hospital for Children of the Nemours Foundation
    Wilmington, Delaware 19803, United States
  • Miami Children's Research Institute
    Miami, Florida 33136, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Children's Hospital of Michigan
    Detroit, Michigan 48201, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10174, United States
  • Albert Einstein College of Medicine
    New York, New York 10467, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Oregon University
    Portland, Oregon 97239, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Texas Transplant Institute
    San Antonio, Texas 78229, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23284, United States
  • Fred Hutchinson Cancer Research
    Seattle, Washington 98109, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, Nemecek E, Neudorf S, Prasad V, Prockop S, Quigg T, Satwani P, Cheng A, Burke E, Hayes J, Skerrett D; MSB-GVHD001/002 Study Group. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2020 May;26(5):845-854. doi: 10.1016/j.bbmt.2020.01.018. Epub 2020 Feb 1. PubMed 32018062 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in Apr 2018, 34 months.

Results were first posted in Mar 2022, 3 years 11 months after primary completion. A results delay was requested in Feb 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2014
First posted
Jan 12, 2015
StartActual
Jun 4, 2015
Primary completionActual
Apr 9, 2018
CompletionActual
Apr 9, 2018
Results delay requested
Feb 4, 2019
Results first posted
Mar 17, 2022
Last update
Mar 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02336230
Lead sponsor
Mesoblast, Inc.
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Jan 12, 2015
Start date
Jun 4, 2015
Primary completion
Apr 9, 2018
Completion
Apr 9, 2018
Results posted
Mar 17, 2022
Last update
Mar 17, 2022

Study contacts

Christopher James
study director · Mesoblast, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remestemcel-l

Start the discussion